

Texas Children’s Designated an Oxalosis & Hyperoxaluria Foundation Care Center of Excellence for Primary Hyperoxaluria

New Paltz, NY (May 21, 2026) – The [Oxalosis & Hyperoxaluria Foundation](http://www.ohf.org) (OHF) today announced that [Texas Children’s](https://www.texaschildrens.org) has been designated an OHF Care Center of Excellence, recognizing the hospital’s expertise in providing specialized, comprehensive care for children and families affected by primary hyperoxaluria (PH), a rare genetic kidney disease.

Texas Children’s is the sixth medical center nationwide and the third pediatric institution to join the OHF Care Center Network, alongside Mayo Clinic, University of Alabama at Birmingham, Boston Children’s Hospital, University of California San Francisco (UCSF), and Children’s Hospital of Philadelphia (CHOP). With additional designations expected in 2026, the network continues to expand access to expert PH care across the United States and internationally.

PH is a rare inherited condition in which the liver produces excessive oxalate, leading to kidney stones, nephrocalcinosis, and progressive kidney damage. Symptoms can appear as early as infancy, and without early diagnosis and appropriate treatment, PH can lead to kidney failure requiring dialysis or a kidney and/or liver transplantation.

As an OHF Care Center of Excellence, Texas Children’s follows the latest evidence-based clinical guidelines for PH diagnosis, treatment, and long-term management and offers access to clinical trials for rare stone disorders when available.

“Because primary hyperoxaluria can lead to recurrent kidney stones and risk of kidney failure – sometimes as early as infancy – early diagnosis and highly specialized care are essential,” said Dr. [Mini Michael](#), pediatric nephrologist, Medical Director of the Pediatric Kidney Stone Clinic, and lead physician of the OHF Care Center at Texas Children’s. “Until the recent availability of a novel RNA interference (RNAi) therapy, treatment for PH was largely supportive, and many patients with PH1 and PH2 ultimately required kidney and/or liver transplantation. These advances have shifted our focus toward early diagnosis and timely treatment to prevent kidney failure and improve long-term outcomes. This designation reflects our commitment to evidence-based care, multidisciplinary collaboration, and long-term support for children and families affected by PH.”

Texas Children’s multidisciplinary team — including nephrology, urology, genetics, dialysis, transplant, and dedicated support services — delivers integrated, family-centered care while incorporating the latest advances in PH treatment.

“We have had a steady increase in young patients with kidney stones,” said Dr. [Nicolette Janzen](#), pediatric urologist and Surgical Director of the Pediatric Kidney Stone Clinic at Texas Children’s. “By integrating some of the newest technologies in the care of our patients, our stone-free rate has improved significantly, allowing us to improve PH patients’ quality of life.”

“We are proud to welcome Texas Children’s into the OHF Care Center Network,” said Kim Hollander, Executive Director of OHF. “With four new Centers of Excellence designated over the past year including Texas Children’s, we are seeing strong momentum across the clinical community to close gaps in primary hyperoxaluria care and ensure that no patient or family has to navigate this disease alone.”

Because PH is often underdiagnosed, families frequently face challenges finding knowledgeable providers and coordinated care. Texas Children’s designation helps address this gap for patients in Houston, the Southeast Texas and Upper Gulf Coast regions, and beyond.

About OHF

The Oxalosis and Hyperoxaluria Foundation is the world’s largest private funder of hyperoxaluria research. Dedicated to finding a cure, OHF puts patients first — advancing research, improving care, and empowering those living with the disease.

www.ohf.org